Naldemedine

(Symproic®)

Naldemedine

Drug updated on 11/14/2023

Dosage FormTablet (oral: 0.2 mg)
Drug ClassOpioid antagonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

Product Monograph / Prescribing Information

Document TitleYearSource
Symproic (Naldemedine) Prescribing Information.2020BioDelivery Sciences International, Inc., Raleigh, NC

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines